What are the newest treatments for HER2-positive metastatic breast cancer?
Thank you for your response. The answer is under review
THANK YOU. Your feedback can help the system identify problems.
    What are the newest treatments for HER2-positive metastatic breast cancer?
    Updated:25/05/2024
    Submit
    1 Answers
    DesertLight
    Updated:23/04/2024

    Recent advancements in HER2-positive metastatic breast cancer treatments are reshaping patient outcomes.

    Frequently Asked Questions (FAQ)
    • Q1: What is HER2-positive metastatic breast cancer?
    • A1: It is a subtype of breast cancer characterized by overexpression of the human epidermal growth factor receptor 2 (HER2), indicating a more aggressive disease progression.
    • Q2: What are the latest targeted therapies?
    • A2: New targeted therapies include tucatinib, neratinib, and antibody-drug conjugates like trastuzumab deruxtecan (DS-8201).
    • Q3: How do these treatments work?
    • A3: These therapies inhibit HER2 signaling pathways or deliver cytotoxic agents directly to HER2-positive cancer cells, enhancing treatment efficacy.
    • Q4: What are the side effects of these therapies?
    • A4: Side effects may include diarrhea, nausea, fatigue, and risk of heart problems; monitoring is essential.
    • Q5: What is the role of immunotherapy?
    • A5: Immunotherapy, including checkpoint inhibitors, is being explored as a potential treatment option to enhance the immune response against HER2-positive tumors.
    Statistics
    Treatment Type Progression-Free Survival (PFS)(Months) Overall Survival (OS)(Months)
    Standard HER2 Therapies (Trastuzumab + Taxane) 10 25
    Tucatinib + Trastuzumab + Capecitabine 12.5 30.9
    Trastuzumab Deruxtecan 16.4 34.0
    Comparison of New Treatments
    Treatment Mechanism of Action Year Approved
    Tucatinib Selective HER2 inhibitor 2020
    Neratinib Tyrosine kinase inhibitor 2017
    Trastuzumab Deruxtecan Antibody-drug conjugate 2020
    Mind Map Summary
    • HER2-positive Metastatic Breast Cancer
      • Classification
      • Treatment Options
        • Targeted Therapies
        • Immunotherapy
        • Clinical Trials
      • Side Effects
      • Patient Monitoring
      • Future Directions
    Conclusion

    The evolving landscape of HER2-positive metastatic breast cancer treatment offers hope for patients, with targeted therapies and immunotherapies leading the charge.

    Upvote:505